Boston, Massachusetts, USA, November 14, 2026
Servier Pharmaceuticals has announced updated four-year results from the Phase 2 FIREFLY-1 clinical study evaluating OJEMDA® (tovorafenib) in children, adolescents and young adults with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). The findings were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia, providing additional evidence about the long-term treatment outcomes associated with this targeted cancer therapy. The analysis included patients aged six months to 25 years and evaluated outcomes over an extended follow-up period, including treatment duration, time to subsequent therapy and treatment-free intervals after discontinuation. Among 76 efficacy-evaluable patients, the median time to next treatment reached 50.9 months, highlighting the potential for prolonged disease management following tovorafenib treatment. The findings also demonstrated that some patients remained off treatment for at least two years after discontinuation. These results provide important information for healthcare professionals and families managing pediatric brain tumours, where treatment decisions must consider both disease control and the long-term effects of therapy on childhood growth and development.
FIREFLY-1 Study Demonstrates Long-Term Treatment Outcomes
The Phase 2 FIREFLY-1 trial is investigating tovorafenib in patients with relapsed or refractory pediatric low-grade glioma carrying specific BRAF alterations. The updated analysis included a median study duration of 52.5 months in the registrational arm, based on the June 5, 2026, data cutoff. Patients received oral OJEMDA once weekly in 28-day treatment cycles for 26 cycles, with the option to continue treatment or enter an optional post-treatment observation period. One of the important findings was the median time to next treatment of 50.9 months among 76 efficacy-evaluable patients, compared with 42.6 months reported in the previous three-year analysis presented at SNO 2025. This improvement in the reported median duration provides further insight into the longer-term treatment experience of patients receiving tovorafenib. The analysis also examined outcomes after treatment discontinuation to better understand how long patients could remain without additional therapy. Among the 41 patients who entered the optional post-treatment observation period, 76% remained treatment-free for at least 12 months, while 54% remained treatment-free for at least 24 months. The median treatment-free interval had not been reached at the time of analysis. These findings suggest that certain patients may experience extended periods without requiring additional anticancer treatment following OJEMDA therapy.
Treatment-Free Intervals and Safety Findings
The updated analysis also evaluated tumour behaviour following discontinuation of tovorafenib. Among the 41 patients entering post-treatment observation, 54% experienced tumour rebound, while seven patients were retreated with OJEMDA. Eleven patients, representing 27% of this group, received OJEMDA again, and nine had smaller tumours than before retreatment at their last available scan. These findings provide additional information about the management of disease progression after stopping therapy and the potential role of retreatment in selected patients. The safety profile remained consistent with the previously established profile of OJEMDA. In the safety analysis population of 137 patients, the most common Grade 3 or higher treatment-related adverse events included reduced growth velocity (36%), anaemia (14%), increased creatine phosphokinase (CPK) levels (11%), maculopapular rash (8%) and increased alanine aminotransferase (ALT) levels (5%). Importantly, no treatment-related deaths were reported, and no additional treatment discontinuations due to treatment-related adverse events occurred after the three-year data cutoff. The growth analysis also showed that 88% of patients demonstrated growth recovery, irrespective of the degree of growth suppression experienced during treatment. Continued monitoring of growth and other safety parameters remains important when treating children with targeted cancer therapies.
OJEMDA Advances Targeted Treatment for Pediatric Brain Tumours
OJEMDA (tovorafenib) is an oral Type II RAF kinase inhibitor that targets mutant BRAF V600, wild-type BRAF and wild-type CRAF kinases. It is designed to interfere with abnormal RAF signalling pathways involved in the growth and survival of cancer cells. The medicine is indicated in the United States for patients aged six months and older with relapsed or refractory pediatric low-grade glioma harbouring a BRAF fusion or rearrangement, or a BRAF V600 mutation. Its approval was granted under the FDA’s accelerated approval pathway based on tumour response rate and duration of response, with continued approval potentially dependent on confirmation of clinical benefit through additional studies. Pediatric low-grade glioma is the most common type of brain tumour in children, and BRAF alterations account for more than 50% of cases worldwide. Although many affected children survive, recurrent disease can require multiple treatment interventions, potentially affecting neurological function, vision, hormone regulation and physical development. The latest FIREFLY-1 findings strengthen the available long-term evidence for tovorafenib and provide additional information for treatment discussions between clinicians and families. Servier’s continued evaluation of OJEMDA highlights the importance of developing targeted therapies that balance tumour control, long-term safety and quality of life for children living with brain cancer.
Source: Servier Pharmaceuticals press release



